Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

astrazeneca spa - budesonide - capsule - "3 mg capsule rigide a rilascio modificato" 50 capsule

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

dr. falk pharma gmbh - budesonide - budesonide

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

tillotts pharma ag - budesonidum - clistere - i) dispergierbare tablette: budesonidum 2.3 mg, lactosum, riboflavini natrii phosphas, crospovidonum, silica colloidalis anhydrica, magnesii stearas pro compresso. ii) vehikel: e 218 80 mg, propylis parahydroxybenzoas 20 mg, natrii chloridum, aqua purificata ad solutionem pro 100 ml. suspensio reconstituta: budesonidum 2 mg, lactosum, riboflavini natrii phosphas, crospovidonum, silica colloidalis anhydrica, magnesii stearas, e 218 80 mg, propylis parahydroxybenzoas 20 mg, natrii chloridum, aqua purificata ad suspensionem pro 100 ml. - la colite ulcerosa - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - budesonidum - capsule - budesonidum 3 mg, sacchari sphaerae corresp. saccharum 276 mg et maydis amylum, lactosum monohydricum 12 mg, povidonum k 25, acidi methacrylici et methylis methacrylatis polymerisatum 1:1, acidi methacrylici et methylis methacrylatis polymerisatum 1:2, ammonio methacrylatis copolymerum b, ammonio methacrylatis copolymerum a, triethylis citras, talcum, kapselhülle: gelatina, e 172 (rubrum), e 171, e 127, e 172 (nigrum), natrii laurilsulfas corresp. natrium 0.006 mg, pro capsula. - morbus chron, kollagene colitis - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

tillotts pharma ag - budesonidum - hartkapsel mit veränderter wirkstofffreisetzung - budesonidum 3 mg, tributylis acetylcitras, simeticonum, ethylcellulosum, acidi methacrylici et ethylis acrylatis polymerisati 1:1 dispersio 30 per centum, polysorbatum 80, sacchari sphaerae 320 mg, talcum, triethylis citras, kapselhülle: gelatina, paraffinum liquidum, silica colloidalis anhydrica, natrii laurilsulfas corresp. natrium 11.96 µg, e 171, e 172 (rubrum), e 172 (nigrum), e 172 (flavum), drucktinte: ammonii hydroxidum, e 172 (nigrum), kalii hydroxidum, lacca, pro capsula. - morbus crohn, mikroskopische kolitis - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - budesonidum - rektalschaum - budesonidum 2 mg, propylenglycolum 600.3 mg, alcohol cetylicus et stearylicus 12.6-15.12 mg, polysorbatum 60, macrogoli 10 aether stearylicus, alcohol cetylicus 8.4 mg, acidum citricum monohydricum, dinatrii edetas, aqua purificata ad emulsionem pro dosi, propellentia: butanum, isobutanum, propanum. - la colite ulcerosa - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - budesonidum - magensaftresistentes granulat - budesonidum 9 mg, sacchari sphaerae corresp. saccharum 828 mg, lactosum monohydricum 36 mg, povidonum k 25, acidi methacrylici et methylis methacrylatis polymerisatum 1:1, acidi methacrylici et methylis methacrylatis polymerisatum 1:2, ammonio methacrylatis copolymerum b, ammonio methacrylatis copolymerum a, triethylis citras, talcum, aromatica zitrone cum citralum et citronellolum et limonenum et geraniolum et linaloolum, xanthani gummi, sorbitolum 899.5 mg, acidum citricum, sucralosum, magnesii stearas, ad granulatum pro charta. - morbus crohn, kollagene colitis - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ferring ag - budesonidum - retardtabletten - budesonidum 9 mg, acidum stearicum, lecithinum ex soja, cellulosum microcristallinum, hydroxypropylcellulosum, lactosum monohydricum corresp. lactosum 47.5 mg, silica colloidalis hydrica, magnesii stearas, Überzug: acidi methacrylici copolymerum a, acidi methacrylici copolymerum b, talcum, triethylis citras, e 171 pro compresso obducto. - da lieve a moderatamente grave colite ulcerosa - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

dr. falk pharma gmbh - budesonide - malattie esofagee - antidiarrheals, intestinali antiinfiammatori / antinfettivo agenti - jorveza è indicato per il trattamento della esofagite eosinofila (eoe) negli adulti (di età superiore a 18 anni).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - budesonidum - compresse orodispersibili - budesonidum 1 mg, dinatrii citras sesquihydricus, natrii dihydrogenocitras anhydricus, natrii hydrogenocarbonas, sucralosum, povidonum k 25, natrii docusas, mannitolum, macrogolum 6000, magnesii stearas pro compresso corresp. natrium 25.62 mg. - bei erwachsenen zur behandlung der eosinophilen Ösophagitis (eoÖ) - synthetika